Vaccines: India's Universal Immunization Programme, Vaccine Maitri, and the Next-Gen Tech Horizon

The Shield of Immunity: Charting India’s Vaccine Journey

The concept of vaccination, a cornerstone of modern public health, represents one of humanity’s greatest triumphs over disease. From Edward Jenner’s pioneering work with cowpox in the 18th century to the global eradication of smallpox in 1980, vaccines have saved countless lives and transformed societies. For India, a nation of over 1.4 billion people, a robust and equitable immunization strategy is not just a health policy but a fundamental pillar of national development, social security, and economic stability. India’s journey in this domain is a compelling narrative of scaling up, innovation, and global leadership, culminating in its widely recognized status as the ‘pharmacy of the world’.

This journey has been institutionalized through the Universal Immunization Programme (UIP), one of the largest and most ambitious public health initiatives on the planet. However, the COVID-19 pandemic served as both a severe test and a powerful catalyst, exposing vulnerabilities in supply chains and healthcare delivery while simultaneously accelerating technological adoption and reinforcing India’s critical role in global vaccine manufacturing. As the world grapples with the lessons from the pandemic and negotiates a new global architecture for pandemic preparedness, India stands at a crucial juncture. The nation is not only expanding its domestic immunization coverage with new life-saving vaccines but is also investing in next-generation platforms like mRNA technology and shaping the global discourse on vaccine equity. This article provides a comprehensive analysis of India’s vaccination landscape, from the foundational UIP to the strategic imperatives of Mission Indradhanush, the diplomatic dimensions of Vaccine Maitri, and the technological frontiers that will define the future of public health.

Fun Fact: The term “vaccine” itself originates from the Latin word ‘vacca’, meaning cow. This is a direct tribute to Edward Jenner’s pioneering 1796 experiment, where he used material from cowpox pustules to protect a young boy from the far more deadly smallpox.

The Bedrock of Public Health: The Universal Immunization Programme (UIP)

Launched in 1985, India’s Universal Immunization Programme (UIP) is the backbone of its preventive healthcare strategy. It evolved from the Expanded Programme on Immunization (EPI), which began in 1978. The UIP’s primary objective is to provide free, life-saving vaccines to all children and pregnant women, protecting them against a dozen vaccine-preventable diseases. Annually, it targets an estimated 2.67 crore newborns and 2.9 crore pregnant women. The scale of this operation is immense, relying on a vast network of healthcare workers, a complex cold chain system, and a steady supply of vaccines, a majority of which are produced domestically.

The program has been instrumental in dramatically reducing child mortality and morbidity. Landmark achievements include the elimination of polio in 2014 and maternal and neonatal tetanus in 2015. The UIP is a dynamic program, continuously evolving to include new vaccines based on epidemiological data and disease burden. The vaccines currently provided under the program protect against: Tuberculosis (BCG), Diphtheria (DPT), Pertussis (Whooping Cough), Tetanus (TT), Polio, Hepatitis B, Pneumonia and Meningitis due to Haemophilus influenzae type b (Hib), Measles, Rubella, Japanese Encephalitis (JE) (in endemic districts), and Rotavirus Diarrhea. The Pneumococcal Conjugate Vaccine (PCV) was also rolled out nationwide in 2021, marking a significant step against pneumococcal pneumonia.

A critical component underpinning the UIP’s success is the Electronic Vaccine Intelligence Network (eVIN), a technology solution that digitizes the entire vaccine stock management system. It provides real-time information on vaccine stocks and flows, and storage temperatures across all cold chain points. This has been crucial in reducing vaccine wastage and ensuring availability. This system’s robustness was a precursor to the development of the Co-WIN platform.

Mnemonic for UIP-Covered Diseases: To remember the key diseases, think of the phrase: “To Defeat Painful Threats, Protect Healthy Mothers & Radiant Rare Jewels.”

• T - Tuberculosis (BCG)
• D - Diphtheria
• P - Pertussis
• T - Tetanus
• P - Polio
• H - Hepatitis B & Hib
• M - Measles
• R - Rubella
• R - Rotavirus
• J - Japanese Encephalitis

Accelerating Coverage: The Mission Indradhanush Saga

Despite the UIP’s success, pockets of low immunization coverage persisted across the country, leading to continued outbreaks of vaccine-preventable diseases. To address these gaps and achieve full immunization for all, the Government of India launched Mission Indradhanush in December 2014. The mission’s name, meaning ‘Rainbow’, symbolizes its goal of protecting children against multiple diseases.

The core strategy of Mission Indradhanush is to conduct targeted drives in high-priority districts and urban areas with a large number of unvaccinated and partially vaccinated children. It employs a “catch-up” campaign approach, aiming to cover all children under two years of age and pregnant women who were missed during routine immunization rounds. This involves meticulous micro-planning, where every village and urban pocket is mapped to identify beneficiaries, followed by intensive community mobilization through ASHAs and Anganwadi workers, and robust monitoring.

Phases of Intensification: The mission has evolved through several phases, each refining the strategy and expanding its reach:

1. Mission Indradhanush (2014-2017): The initial phases focused on micro-planning, robust monitoring, and intensive community engagement to build awareness and overcome vaccine hesitancy.
2. Intensified Mission Indradhanush (IMI) (2017): This phase aimed to reach every child under two and all pregnant women in selected districts and cities to ensure full immunization coverage by 2018, ahead of the original 2020 target.
3. IMI 2.0 (2019-2020): Launched to commemorate 25 years of the Pulse Polio Programme, IMI 2.0 targeted 272 districts across 27 states, with a focus on tribal and hard-to-reach areas.
4. IMI 3.0 (2021): This phase focused on children and pregnant women who had missed vaccine doses during the COVID-19 pandemic, which had severely disrupted routine health services.
5. IMI 4.0 (2022): It aimed to contribute to India’s commitment to achieving Sustainable Development Goal 3 (Good Health and Well-being) by reducing child mortality. It was conducted in 416 districts across 33 states/UTs.
6. IMI 5.0 (2023): The latest iteration, launched in 2023, marked a significant shift by integrating with the U-WIN digital platform. It focused for the first time on children up to 5 years of age (previously 2 years) and aimed to eliminate Measles and Rubella by 2023.

The U-WIN platform is a game-changer, designed to be the digital backbone for immunization in India. Modeled on the successful Co-WIN portal, U-WIN creates a unique health ID (ABHA ID) for each pregnant woman and child, maintaining a digital, real-time record of their vaccination status. This allows for better tracking, reduces dropout rates, and provides beneficiaries with digital vaccination certificates, which can be accessed anywhere in the country.

Statistic: As of early 2023, the various phases of Mission Indradhanush have collectively reached over 5 crore children and 1 crore pregnant women, significantly boosting India’s full immunization coverage from around 67% in 2014 to over 76% nationally, with many districts showing much higher improvements.

The COVID-19 Catalyst: Atmanirbharta and Vaccine Maitri

The COVID-19 pandemic was an unprecedented global crisis that tested India’s public health infrastructure, scientific prowess, and manufacturing capacity. India’s response was multi-pronged, resting on the pillars of Atmanirbhar Bharat (self-reliant India) and global cooperation.

Domestic Response & Technological Leap:

• Indigenous Vaccine Development: The development of Covaxin by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) was a landmark achievement. As an inactivated whole-virion vaccine, it demonstrated India’s capability in end-to-end vaccine development.
• Manufacturing Powerhouse: The Serum Institute of India (SII), already the world’s largest vaccine manufacturer by volume, partnered with AstraZeneca to produce Covishield. This massive manufacturing scale was the engine of India’s vaccination drive and its global supply efforts.
• Digital Infrastructure: The Co-WIN (Covid Vaccine Intelligence Network) platform was a monumental success in digital governance. It managed the entire vaccination process—from registration and slot booking to real-time tracking of doses and issuing digital certificates—for a billion-plus population. It has since been offered as a digital public good to other countries.

Vaccine Maitri: Diplomacy Through Health: In early 2021, as its domestic vaccination drive began, India launched the Vaccine Maitri (Vaccine Friendship) initiative. Under this program, India supplied millions of ‘Made in India’ COVID-19 vaccines to countries across the globe, both as grants and commercial sales. Over 280 million doses were supplied to more than 100 countries. This act of health diplomacy earned India immense goodwill and reinforced its credentials as a reliable partner and the ‘pharmacy of the world’. While the initiative faced a temporary pause during India’s devastating second wave in mid-2021 to prioritize domestic needs, it cemented India’s role in global health security.

The New Frontier: Next-Gen Vaccines and Pandemic Preparedness

The lessons from COVID-19 have spurred a new wave of innovation and policy focus in India’s vaccine sector. The emphasis is now on expanding the UIP basket, fostering indigenous R&D for futuristic platforms, and building a robust architecture for future pandemic preparedness.

Expanding the UIP Basket:

• Pneumococcal Conjugate Vaccine (PCV): After a phased introduction, the PCV was rolled out nationwide in 2021 under the UIP to protect children from pneumococcal pneumonia, a major cause of child mortality.
• Human Papillomavirus (HPV) Vaccine: A significant development in 2023-2024 has been the government’s push to introduce the indigenous HPV vaccine, Cervavac, into the UIP. Developed by the Serum Institute of India, this vaccine is crucial for preventing cervical cancer, the second-most common cancer among women in India. The government plans to roll it out for girls aged 9-14 years, a move that could save thousands of lives annually.

Indigenous R&D in Advanced Platforms: India is actively working to reduce its reliance on foreign technology for next-generation vaccines.

• mRNA Vaccines: India’s first indigenous mRNA vaccine, GEMCOVAC-19, developed by Gennova Biopharmaceuticals, received emergency use authorization. While it came later in the pandemic, the development of the platform technology is a strategic asset. The government is now supporting the development of more stable mRNA platforms that do not require ultra-cold storage.
• Nasal Vaccines: Bharat Biotech’s iNCOVACC became the world’s first intranasal COVID-19 vaccine to be approved. As a needle-free mucosal vaccine, it offers easier administration and has the potential to block transmission by generating immunity in the nasal passages, the virus’s entry point.
• DNA Vaccines: Zydus Cadila’s ZyCoV-D, a plasmid DNA vaccine, was another world-first from India. Though its rollout was limited, the development of a three-dose needle-free DNA platform adds another tool to the country’s technological arsenal.

Fun Fact: Unlike traditional vaccines that introduce a weakened virus or a piece of it, mRNA vaccines are like instruction manuals. They deliver a genetic code (mRNA) that teaches our own cells how to make a specific, harmless piece of the virus (like the spike protein). Our immune system then learns to recognize and fight this protein, preparing it for a real infection without ever being exposed to the actual virus.

Comparative Analysis of Vaccine Platforms

Global Health Diplomacy: The WHO Pandemic Accord

A major diplomatic focus for India post-COVID has been the negotiation of a new international instrument on pandemic prevention, preparedness, and response, often called the WHO Pandemic Accord. These negotiations, which have been ongoing through 2023 and 2024, are critical for establishing a more equitable global health architecture.

India, along with other developing nations, has championed the principle of Common but Differentiated Responsibilities and Respective Capabilities (CBDR-RC). India’s key negotiating stance revolves around:

1. Equitable Access: Ensuring that all countries have timely and affordable access to medical countermeasures, including vaccines, diagnostics, and therapeutics, during a health crisis. This is a direct lesson from the “vaccine apartheid” seen in the early days of the COVID-19 pandemic.
2. Technology Transfer: Advocating for mechanisms that facilitate the voluntary or mandatory transfer of technology and know-how to developing countries to enable distributed manufacturing.
3. Benefit-Sharing: A core demand is that the WHO Pathogen Access and Benefit-Sharing (PABS) System must be legally binding. This means that countries and entities that access pathogens from a particular location must share the benefits—such as the resulting vaccines and treatments—with the global community on fair terms.
4. Intellectual Property (IP) Rights: Pushing for a more flexible approach to IP rights during pandemics, including time-bound waivers of certain provisions of the TRIPS agreement to scale up production.

Critical Policy Appraisal

Analytical Lens: UPSC Focus (Mains & Prelims)

Conceptual Basis: The legal and policy framework for immunization in India is rooted in the Constitution of India. While health is a State Subject (Entry 6, List II), the Union Government plays a crucial role under its powers related to international health regulations and preventing the inter-state spread of disease (Entry 29, List III - Concurrent List). More fundamentally, the Right to Health is interpreted as an integral part of the Right to Life and Personal Liberty under Article 21. The National Health Policy (2017) explicitly aims to increase immunization coverage and guides the strategic direction of programs like UIP and Mission Indradhanush.

UPSC Integration: Connecting the Dots:

• Polity & Governance (GS Paper 2): The topic is a classic example of cooperative federalism, where the Centre provides funding, vaccines, and technical guidelines, while states are responsible for implementation. It also showcases digital governance (Co-WIN, U-WIN) and the role of public health in social justice.
• Economy (GS Paper 3): It links directly to the pharmaceutical industry, issues of Intellectual Property Rights (TRIPS), the economic burden of disease, and the concept of Digital Public Infrastructure (DPI) as a driver of growth and efficiency.
• International Relations (GS Paper 2): Vaccine Maitri is a prime example of India’s health diplomacy and soft power. The negotiations at the WHO for the Pandemic Accord are a key aspect of contemporary global governance and India’s role in shaping it.
• Science & Technology (GS Paper 3): The development of different vaccine platforms (mRNA, viral vector, nasal) is a core topic in biotechnology. The challenges of cold chain management are a matter of S&T application in logistics.

Future Impact & Policy Relevance: India’s journey through the pandemic has solidified its position as a global health powerhouse. The future policy direction will likely focus on three strategic pillars:

1. Pandemic Preparedness: Moving beyond a reactive stance to a proactive one by investing in platform technologies that allow for rapid vaccine development (‘Mission 100 Days’), strengthening disease surveillance, and building a stockpile of critical medical supplies.
2. Strengthening Primary Healthcare: Integrating immunization more deeply with nutrition, maternal health, and non-communicable disease screening at the primary healthcare level (Ayushman Arogya Mandirs).
3. Global Leadership: Using its manufacturing capacity and R&D prowess to act as a provider of global public goods, thereby strengthening its claim for a greater role in global decision-making bodies.

Prelims Practice Question (MCQ):

Which of the following diseases are covered under India’s Universal Immunization Programme (UIP) for nationwide rollout?

1. Tuberculosis
2. Dengue
3. Japanese Encephalitis
4. Rubella
5. Pneumococcal Pneumonia

Select the correct answer using the code given below: (a) 1, 4 and 5 only (b) 1, 3, 4 and 5 only (c) 1, 2, 3 and 4 only (d) All of the above

Answer: (a) 1, 4 and 5 only Explanation: The Universal Immunization Programme (UIP) provides vaccines against Tuberculosis (BCG), Rubella (as part of MMR), and Pneumococcal Pneumonia (PCV) on a nationwide basis. The vaccine for Japanese Encephalitis (JE) is also part of the UIP but is provided only in endemic districts, not as a universal nationwide rollout for all beneficiaries. There is currently no vaccine for Dengue included in the UIP. Therefore, only 1, 4, and 5 are covered under a universal nationwide mandate.

Mains Sample Question (15 Marks):

Critically analyze the evolution of India’s Universal Immunization Programme (UIP), with special emphasis on the strategic shifts brought by Mission Indradhanush and the U-WIN platform. In the context of the COVID-19 pandemic, discuss how ‘Vaccine Maitri’ and the push for indigenous next-generation vaccine technologies are shaping India’s role in global health security.

Mind Map Outline (Revision Structure)

• India’s Vaccine Ecosystem
  • Historical Context
    • Edward Jenner & Smallpox Eradication
    • Role as ‘Pharmacy of the World’
  • Universal Immunization Programme (UIP)
    • Foundation: Launched 1985, targets newborns & pregnant women.
    • Key Achievements: Polio-free (2014), Maternal & Neonatal Tetanus free (2015).
    • Diseases Covered (Mnemonic):
      • Tuberculosis (BCG)
      • Diphtheria, Pertussis, Tetanus (DPT)
      • Polio, Hepatitis B, Hib
      • Measles, Rubella, Rotavirus
      • Japanese Encephalitis (endemic areas)
      • Pneumococcal Pneumonia (PCV)
    • Supporting Technology: Electronic Vaccine Intelligence Network (eVIN).
  • Mission Indradhanush (MI)
    • Objective: Address immunization gaps and achieve full coverage.
    • Strategy: Targeted drives, micro-planning, community mobilization.
    • Evolution (Phases):
      • Initial Phases (2014-17)
      • Intensified Mission Indradhanush (IMI 1.0 to 5.0)
      • IMI 5.0 (2023): Focus on children up to 5 years, Measles-Rubella elimination goal.
    • Digital Integration: The U-WIN Platform (digital records, tracking, ABHA ID).
  • COVID-19 Pandemic Response
    • Atmanirbhar Bharat (Self-Reliance):
      • Covaxin: Indigenous inactivated virus vaccine (Bharat Biotech & ICMR).
      • Covishield: Manufacturing partnership (SII & AstraZeneca).
      • Co-WIN Platform: Digital backbone for the world’s largest vaccination drive.
    • Vaccine Maitri (Health Diplomacy):
      • Supplied over 280 million doses to 100+ countries.
      • Enhanced India’s soft power and global standing.
  • Next-Generation Vaccine Technology
    • New UIP Additions:
      • Cervavac: Indigenous HPV vaccine for cervical cancer prevention.
    • Indigenous R&D Platforms:
      • mRNA: GEMCOVAC-19 (Gennova).
      • Intranasal: iNCOVACC (Bharat Biotech).
      • DNA: ZyCoV-D (Zydus Cadila).
    • Comparative Table of Platforms: Inactivated, Live-Attenuated, Viral Vector, mRNA, Subunit.
  • Global Health & Diplomacy
    • WHO Pandemic Accord Negotiations:
      • India’s Stance: Equity, Technology Transfer, Benefit-Sharing (PABS), IP Rights flexibility (TRIPS waiver).
  • Policy Analysis & UPSC Focus
    • Critical Policy Appraisal (Table):
      • Challenges: Hesitancy, logistics, digital divide.
      • Opportunities: Manufacturing scale, digital infra, PPP.
    • Constitutional & Legal Basis:
      • Article 21 (Right to Health).
      • Health as State Subject vs. Union’s role.
      • National Health Policy, 2017.
    • Inter-Topic Linkages:
      • Polity (Federalism, Governance)
      • Economy (Pharma, IPR, DPI)
      • IR (Diplomacy, WHO)
      • S&T (Biotechnology)